²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°é

English

²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°éÉúÎïѪ˨ËÄÏî | ΪDICÔçÆÚÕï¶ÏÌṩÓÐÁ¦Ö§³Ö

Ðû²¼ÓÚ£º2024-12-20

ÎÄÕÂȪԴ£º[ÖÐÎÄ]²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°éÉúÎï




01

DIC¸ÅÊö


ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪ£¨disseminated intravascular coagulation £¬DIC£©ÊÇÔÚÐí¶à¼²²¡»ù´¡ÉÏ £¬Ö²¡ÒòËØËðÉË΢Ѫ¹Üϵͳ £¬µ¼ÖÂÄýѪ»î»¯ £¬È«Éí΢Ѫ¹ÜѪ˨Ðγɡ¢ÄýѪÒò×Ó´ó×ÚÏûºÄ²¢¼Ì·¢ÏËÈÜ¿º½ø £¬ÒýÆðÒÔ³öѪ¼°Î¢Ñ­»·Ë¥½ßΪÌØÕ÷µÄÁÙ´²×ÛºÏÕ÷¡£


DIC²»ÊÇÒ»¸ö×ÔÁ¦µÄ¼²²¡ £¬¶øÊÇÖڶ༲²¡ÖØ´ó²¡ÀíÀú³ÌÖеÄÖÐÐÄ»·½Ú £¬Æä»ù´¡¼²²¡»òÓÕÒò°üÀ¨£ºÑÏÖØѬȾ£¨Å§¶¾Ö¢µÈ£©¡¢¶ñÐÔÖ×Áö¡¢²¡Àí²ú¿Æ¡¢Íâ¿ÆÊÖÊõ¼°ÍâÉËÖж¾ºÍÃâÒßËðÉËµÈ £¬ÆäÖÐѬȾÊÇ×î³£¼ûµÄÔµ¹ÊÔ­ÓÉ¡£


DIC¼²²¡Ìص㣺Æð²¡ÒþÄä £¬ÔçÆÚ¿ÉÎÞÏÔÖøÌØÕ÷ £¬¾ßÓÐÏ£Íû¿ì¡¢Ô¤ºó²î¡¢éæÃüÂʸߵÈ¡£


DICʹ»¼ÕßÆ÷¹ÙË¥½ßºÍéæÃüµÄΣÏÕÐÔÏÔ×ÅÔöÌí £¬ÔÚ²î±ð±¨µÀÖÐ £¬DIC»¼Õß²¡ËÀÂʸߴï31%~86% £¬Òò´ËÓÐѧÕß°ÑDICг³ÆΪ¡°Death Is Coming¡±¡£ÓÉÓÚDIC»ù´¡¼²²¡ºÍÁÙ´²ÌåÏÖ¶àÑù»¯¡¢·ÖÆÚÖØ´ó £¬Ê¹ÆäÈÝÒ×ÓëÆäËûÒýÆð³öÄýѪÒì³£¼²²¡Ïà»ìÏý £¬¼«Ò×±»ºöÊÓ £¬ÑÏÖØÓ°Ï컼ÕßÔ¤ºó £¬Òò´ËDICµÄÔçÆÚÕï¶ÏÊÇDICÕïÖεÄÒªº¦¡£





²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°éÉúÎïѪ˨ËÄÏîÒÑÈ¡µÃ×¢²áÖ¤ £¬ÔÚDICÔçÆÚÕï¶Ï¿ÉÒÔÌṩÓÐÁ¦Ö§³Ö£¡



02

DICÕï¶Ï±ê×¼µÄÏÖ×´


DICµÄ±¬·¢ÆøÖÆÖØ´ó £¬Ö²¡ÒòËزî±ð £¬Æä¶ÔÓ¦µÄ²¡ÀíÐÄÀí»úÖƼ°ÁÙ´²ÌصãÒ²±£´æºÜ´ó²î±ð £¬DICµÄÕï¶ÏÊÇÏÖÔÚÁÙ´²±£´æµÄÒ»¸öÄÑÌâ¡£



ÏÖÔÚÖ¸ÄÏÍƼöʹÓùú¼ÊѪ˨ÓëֹѪѧ»á±ê×¼£¨ISTH-DIC£©¡¢ÖйúDICÕï¶Ï»ý·Öϵͳ£¨CDSS-DIC£©ÆÀ·ÖϵͳÕï¶ÏDIC¡£±ðµÄ £¬2019ÄêISTH¹«²¼ÁËŧ¶¾Ö¢ÐÔÄýѪ²¡(sepsis-induced coagulopathy £¬SIC)Õï¶Ï±ê×¼ £¬ËäÈ»ÏÖ´æÐí¶àDICÕï¶Ï±ê×¼ £¬¿ÉÊǸ÷×Ô±£´æÒ»¶¨µÄ¾ÖÏÞÐÔ £¬¶ÔDICÔçÆÚÕï¶Ï¼°DICÔ¤ºóÅжÏѸËٶȺÍÌØÒì¶È¾ùÓдýÌá¸ß £¬ÓÈÆäÊǶÔéæÃüµÄÅжÏÒÔ¼°pre-DICµÄÕï¶Ï £¬ÏÖÔÚÈÔȱ·¦DICÕï¶ÏµÄ½ð±ê×¼¡£Òò´ËÁÙ´²ÉÏÐèÒªÒÀÍÐеÄÄýѪ·Ö×Ó±ê¼ÇÎィÉèЧÄܸü¸ßµÄDIC¾«×¼Õï¶Ïϵͳ¡£½üÄêÑо¿Ï£Íû¿ì¡¢ÁÙ´²Ö¸µ¼ÒâÒåÇ¿µÄÐÂÐÍÄýѪ·Ö×Ó±ê¼ÇÎï°üÀ¨ÄýѪø-¿¹ÄýѪø¸´ºÏÎï(thrombin-antithrombin compex £¬TAT)¡¢ÏËÈÜø-¿¹ÏËÈÜø¸´ºÏÎï(plasmin antiplasmincomplex £¬PIC)¡¢×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï-ÏËÈÜøԭ¼¤»îÒÖÖÆÎï-1¸´ºÏÎï(tissue plasminogen activator-plasminogen activator inhibitor-l complex £¬t-PAIC)¼°ÑªË¨µ÷ÀíÂÑ°×(thrombomodulin £¬TM)¡£



03
 

ÐÂѪ˨ËÄÏîÖúÁ¦DICÔçÕïÔçÖÎ


2017Äê £¬¡¶ÖлªÑªÒºÑ§ÔÓÖ¾¡·½ÒÏþµÄ¡¶ÃÖÂþÐÔѪ¹ÜÄÚÄýѪÕï¶ÏÖйúר¼Ò¹²Ê¶¡·TAT¿ÉÓÃÓÚDICÔçÆÚÕï¶Ï¡£Í¬Äê £¬ÈÕ±¾ÑªË¨ÓëֹѪѧ»á£¨JSTH£©DICÕï¶Ï±ê×¼ÖÐÒýÈëÁËTAT¼ì²â¡£2020Äê £¬¡¶Öлª¼±ÕïҽѧÔÓÖ¾¡·½ÒÏþµÄ¡¶¼±ÐÔ³öѪÐÔÄýѪ¹¦Ð§ÕÏ°­ÕïÖÎר¼Ò¹²Ê¶¡·ÖÐÖ¸³ö £¬ÑªË¨·Ö×Ó±ê¼ÇÎï £¬TAT¿ÉÔçÆÚÕ¹ÍûѪ˨Ðγɺ͸´·¢Î£º¦ £¬ÔçÆÚÕ¹ÍûDICΣº¦£»PIC¿ÉÓÃÓÚDIC·ÖÐÍ¡¢ÈÜ˨ÖÎÁÆ£»tPAIC¶ÔDIC¡¢ÐÂÎÅÂöѪ˨¾ùÓÐÌáÐÑ×÷Óã»TM¿ÉÌáÐÑѪ¹ÜÄÚƤËðÉ˿ɼûÓÚŧ¶¾Ö¢¡¢Éö¹¦Ð§ÊÜËðºÍ¼±ÐÔ·ÎËðÉ˵È¡£¹ØÓÚÁÙ´²ÇéÐÎÖØ´óµÄ»¼Õß £¬ÍƼöʹÓÃTAT¡¢PIC¡¢tPAIC¡¢TM×÷ÔçÆÚÆÀ¹À¡£


1

TAT  ÄýѪø-¿¹ÄýѪø¸´ºÏÎï

ÌåÄÚÄýѪøÐγɺó £¬²¿·ÖѸËÙÓ뿹ÄýѪø(antithrombin £¬AT)ÍŽáÐγÉTAT £¬¸ÃÖ¸±êÊÇ·´Ó¦ÄýѪøÌìÉúµÄ·Ö×Ó±ê¼ÇÎï £¬¿ÉѸËٵط´Ó¦ÄýѪϵͳµÄ¼¤»îˮƽ £¬Ö±½Ó·´Ó¦ÄýѪϵͳÆô¶¯¡£ÄýѪøÔÚѪҺÖаëË¥ÆÚ½öÊýÃë £¬Ö±½Ó²â¶¨ÄÑÌâ¡£TATµÄѪ½¬°ëË¥ÆÚΪ3~15 min £¬¿ÉÒÔÖ±½Ó²â¶¨ £¬TATѪ½¬Õý³£ÖµÎª<4 ng/mL £¬TAT>4 ng/mL £¬ÌáÐÑÄýѪøºÏ³ÉÔö¶à¡£TATÉý¸ß¿ÉÔçÆÚÕ¹ÍûѪ˨Ðγɺ͸´·¢Î£º¦¡¢ÔçÆÚÕ¹ÍûDICΣº¦¡£

2

PIC  ÏËÈÜø-¿¹ÏËÈÜø¸´ºÏÎï

PICÊÇÏËÈÜøÓëÒÖÖÆÒò×Ó¦Á2¿¹ÏËÈÜøÒÔ1:1ÍŽáÐγɵĸ´ºÏÎï £¬ÊÇÖ±½Ó·´Ó¦ÏËÈÜϵͳ¼¤»îˮƽµÄÉúÎï±ê¼ÇÎï¡£PICѪ½¬°ëË¥ÆÚÔ¼6h £¬¿ÉÖ±½Ó²â¶¨ £¬Ñª½¬Õý³£ÖµÎª<0.8¦Ìg/mL £¬PIC>0.8 ¦Ìg/mL³£ÌáÐÑÏËÈÜϵͳ¼¤»î¡£ÏËÈܼ¤»îˮƽÒòDIC»ù´¡¼²²¡²î±ð¶øÓÐËù²î±ð £¬ÇÒÓëDIC·ÖÐÍÇ×½üÏà¹Ø £¬¿ÉÓÃÓÚÔçÆÚÕ¹Íû¸ßÄý״̬ £¬Ò²¿ÉÓÃÓÚÈÜ˨ÖÎÁƼà²â¡£

3

t-PAIC  ×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï-ÏËÈÜøԭ¼¤»îÒÖÖÆÎï-1¸´ºÏÎï

Ѫ¹ÜÄÚƤϸ°ûËðÉËʱ £¬×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï¼°ÏËÈÜøԭ¼¤»îÒÖÖÆÎï-1ͬʱÊͷŵ½ÑªÒºÖÐ £¬1:1ÍŽáÐγÉtPAIC £¬tPAICÄܹ»·´Ó¦ÄÚƤϸ°ûµÄËðÉË £¬ÊÇÏËÈÜϵͳ¼¤»îµÄ·Ö×Ó±ê¼ÇÎï £¬ÄÐÐÔѪ½¬Õý³£Öµ<17.0 ng/mL £¬Å®ÐÔ<10.5 ng/mL¡£tPAIC ¶ÔDIC¡¢ÐÂÎÅÂöѪ˨¾ùÓÐÌáÐÑ×÷Óà £¬ÊǾ²ÂöѪ˨˨ÈûÖ¢(veinthromboembolism,VTE)¼°ÐĹ£µÄΣº¦Ö¸±ê £¬±ðµÄ¸ÃÖ¸±ê¶ÔDICÕï¶Ï¾ßÓÐÖ÷Òª¼ÛÖµ £¬Ñª½¬Ë®Æ½Éý¸ßÌáÐÑDIC¿ÉÄÜѪ¹ÜÄÚƤϸ°ûËðÉË¡¢ÑªË¨ÐγÉ¡£

4

TM  Ѫ˨µ÷ÀíÂÑ°×

TMΪÄÚƤϸ°ûÍâòµÄÄýѪøÊÜÌå £¬ÒÖÖÆÄýѪøµÄ»îÐÔ £¬ÔöÇ¿ÂÑ°×C»î»¯ÐÔÄÜ £¬Ñª½¬TMÕý³£ÖµÎª3.8~13.3 TU/mL¡£µ±ÄÚƤϸ°ûÊÜËð»ò¹¦Ð§ÕÏ°­Ê± £¬TM±í´ï½µµÍ £¬²¿·ÖTM±»ÂÑ°×øˮ½âÖÁѪ½¬ÖС£Òò´Ë £¬TMÊÇÄÚƤϸ°ûÊÜËðµÄ±ê¼ÇÎï¡£TMÉý¸ßÌáÐÑѪ¹ÜÄÚƤËðÉË £¬¿É¼ûÓÚŧ¶¾Ö¢¡¢Éö¹¦Ð§ÊÜËð¡¢¼±ÐÔ·ÎËðÉ˵È¡£


ÐÂѪ˨ËÄÏîÍŽá¼ì²â¶ÔÕï¶ÏDICµÄ¼ÛÖµ¸ü¸ß


Ò»Ïî¶àÖÐÐÄÇ°Õ°ÐÔÊÓ²ìÑо¿Åú×¢TAT¡¢PIC¡¢tPAICºÍsTMÔÚ²î±ð»ù´¡¼²²¡µÄDIC»¼ÕßÖÐÌåÏÖ³öÓÅÒìµÄÕï¶ÏÐÔÄܺÍÔ¤ºó¼ÛÖµ £¬TAT¡¢tPAICºÍsTMÔÚpre-DICµÄÕï¶Ï¾ßÓÐÒ»¶¨µÄÒâÒå¡£±ðµÄ £¬ÐÂѪ˨ËÄÏîÍŽá¼ì²â¿ÉÔöÌíAUC¡¢Ñ¸ËٶȺÍÓÅÊÆ±È £¬¾ßÓиü¸ßµÄ¼ì²âЧÄÜ £¬ÓÐÖúÓÚʵʱ¸ÉÔ¤¡£



×ÛÉÏËùÊö £¬DIC»ù´¡¼²²¡¶àÑù £¬ÁÙ´²·ÖÆÚÖØ´ó £¬ÓëÆäËûѪ˨ÐÔ¼²²¡µÄÅбðÕï¶Ï½ÏÄÑÌâ £¬¼«Ò×±»ºöÊÓ £¬Ê¹ÓÃͨÀýÄýѪָ±êÕï¶ÏDICʱ £¬DIC»¼ÕßÍùÍùÒѾ­½øÈëÖÐÍíÆÚ £¬´Ëʱ»¼ÕßµÄÔ¤ºóÒ»Ñùƽ³£½Ï²î £¬ÄýѪ¡¢ÏËÈÜϵͳÔÓÂÒ £¬ÄÑÒÔ»Ö¸´Õý³£Ë®Æ½ £¬Ò×±¬·¢¶àÆ÷¹Ù¹¦Ð§ÕÏ°­×ÛºÏÕ÷£¨MODS£© £¬²¡ËÀÂʼ«¸ß¡£ÐÂѪ˨ËÄÏîTM¡¢TAT¡¢PIC¡¢t-PAICÔÚDICÔçÆÚÕï¶ÏÖоßÓÐÖ¸µ¼ÒâÒå £¬²¢ÇÒ±ÈͨÀýÄýѪָ±ê¸üÔçÌáÐÑÄýѪÓëÏËÈÜϵͳÒì³£ £¬Åú×¢Æä¶ÔÔçÆÚDIC¾ßÓÐÓÅÒìµÄÕï¶Ï¼ÛÖµ¡£Í¨¹ýÐÂѪ˨ËÄÏî¼ì²â £¬¿ÉÖúÁ¦ÁÙ´²¾«×¼ÅжÏDICµÄʱÆÚ £¬ÌáÐÑÁÙ´²¼°Ôç¾ÙÐиÉÔ¤²¢µ÷½âÖÎÁƼƻ®¡£




²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°éѪ˨ËÄÏî²úÆ·ÏÈÈÝ


? ÒªÁìѧ£º´Å΢Á£»¯Ñ§·¢¹â·¨

? Ñù±¾ÀàÐÍ£ºèÛéÚËáÄÆѪ½¬

? Ð£×¼ÖÊ¿Ø£ºËæºÐÔùÓè

? ÊÊÓûúÐÍ£ºÈ«ÐÂÈý¿îÈ«×Ô¶¯»¯Ñ§·¢¹âÒÇÆ÷¡£¾ßÓÐÕ¼µØС £¬²âÊÔËÙÂÊ¿ì £¬ÎÞаÐԸߵÈÓÅÊÆ £¬¿ÉÒÔÖª×ã¶àÖÖÖն˿ͻ§ÐèÇó¡£



²Î¿¼ÎÄÏ×

[1] ÖлªÒ½Ñ§»áѪҺѧ·Ö»áѪ˨ÓëֹѪѧ×飮ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕï¶ÏÖйúר¼Ò¹²Ê¶(2017Äê°æ)[J]. ÖлªÑªÒºÑ§ÔÓÖ¾, 2017, 38(5):361-363.

[2] ÍõÁ¦¾ü £¬²ñÑÞ·Ò. ŧ¶¾Ö¢²¢·¢ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕïÖμ±Õïר¼Ò¹²Ê¶[J].ÊÊÓÃÄ¥Á·Ò½Ê¦ÔÓÖ¾, 2017, 03(v.9):7-10.DOI:CNKI:SUN:CJCP.0.2017-03-003.

[3] ºú×ÏÞ±,ÂíÏþ´º.ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕï¶Ï±ê×¼£ºÎÊÌâÓëÆÚÍû[J].ÖйúÊÊÓÃÄÚ¿ÆÔÓÖ¾,2021,41(06):457-461.DOI:10.19538/j.nk2021060101.

[4] Ëξ°´º,ÕÅΰ,ÕÅÀÚ,µÈ.ÖØÖ¢»¼ÕßÄýѪ¹¦Ð§ÕÏ°­±ê×¼»¯ÆÀ¹ÀÖйúר¼Ò¹²Ê¶[J].½â·Å¾üҽѧÔÓÖ¾,2022,47(02):107-117.

[5] ÉÛÃã,ѦÏÔ×Å,Íõ˼¼Ñ,µÈ.¼±ÐÔ³öѪÐÔÄýѪ¹¦Ð§ÕÏ°­ÕïÖÎר¼Ò¹²Ê¶[J].Öлª¼±ÕïҽѧÔÓ,2020,29(6):780-787.

[6] Wada H, Takahashi H, Uchiyama T, et al. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis[J]. Thrombosis Journal, 2017,15(1).

[7] Mei H, Jiang Y, Luo L, et al. Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation: A multi-center prospective observational study. Thromb Res. 2019;173:20-26.


END

ÎÄÕÂȪԴ£º²©88-betb88-Òâ¼×À­Æë°Â¹Ù·½ºÏ×÷»ï°éÉúÎï

Ôð±à£ºEcho

У¶Ô£ºPretty¡¢Miss Jia


 
ÍøÕ¾µØͼ